Exciting Treatment Advances in Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Substantial developments are under way in the treatment of upper tract urothelial cancer (UTUC). Seth P. Lerner, MD, FACS, recently spoke with i3 Health about mitomycin gel (JelmytoTM, UroGen Pharma), now FDA approved as the first agent specifically indicated for the treatment of low-grade UTUC. In this second installment of his interview, Dr. Lerner, principal investigator of the OLYMPUS study, on which the mitomycin gel approval was based, discusses research advances in the treatment of both l...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.